Elan deal boosts Perrigo's international plans

29 July 2013 - Deborah Wilkes

Archived

Perrigo is poised to acquire Elan – the Irish biotechnology company behind the multiple sclerosis drug Tysabri (natalizumab) – in a cash and stock deal worth US$8.6 billion.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: